Targeting neuroblastoma with advanced alpha particle therapy.
Image-guided dosimetry-based alpha particle therapy for neuroblastoma.
['FUNDING_SBIR_2'] · VIEWPOINT MOLECULAR TARGETING, INC. · NIH-10677002
This study is testing a new way to treat neuroblastoma, a common childhood cancer, by using a special therapy that targets cancer cells while trying to keep healthy cells safe, and it's being done in mice that have a similar type of cancer to help make sure it's safe and effective for kids.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VIEWPOINT MOLECULAR TARGETING, INC. (nih funded) |
| Locations | 1 site (Coralville, UNITED STATES) |
| Trial ID | NIH-10677002 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new treatment for neuroblastoma, the most common pediatric cancer, by using a targeted alpha particle therapy that aims to improve tumor response rates. The approach utilizes a genetically engineered mouse model that closely mimics human neuroblastoma to test the effectiveness and safety of the treatment. By targeting the somatostatin receptor 2 (SSTR2) found in neuroblastoma tumors, the therapy aims to deliver radiation directly to the cancer cells while minimizing damage to healthy tissues. The research will also assess potential side effects, particularly on the kidneys, to ensure patient safety.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with neuroblastoma, particularly those who have not responded well to existing treatments.
Not a fit: Patients with neuroblastoma who are not expressing the somatostatin receptor 2 (SSTR2) may not benefit from this targeted therapy.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment outcomes for children with neuroblastoma.
How similar studies have performed: Previous research has shown promising results with similar targeted therapies, indicating potential for success in this novel approach.
Where this research is happening
Coralville, UNITED STATES
- VIEWPOINT MOLECULAR TARGETING, INC. — Coralville, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SCHULTZ, MICHAEL KING — VIEWPOINT MOLECULAR TARGETING, INC.
- Study coordinator: SCHULTZ, MICHAEL KING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers